HomeAGIO • BMV
add
Agios Pharmaceuticals Inc
Previous close
$1,222.00
Year range
$983.02 - $1,222.00
Market cap
1.82B USD
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 10.73M | 51.06% |
Operating expense | 51.70M | 46.43% |
Net income | -96.52M | -0.61% |
Net profit margin | -899.56 | 33.40% |
Earnings per share | -1.74 | -1.16% |
EBITDA | -123.67M | -17.92% |
Effective tax rate | 8.42% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 893.71M | 15.03% |
Total assets | 1.66B | 77.48% |
Total liabilities | 122.24M | -3.06% |
Total equity | 1.54B | — |
Shares outstanding | 57.30M | — |
Price to book | 45.33 | — |
Return on assets | -18.09% | — |
Return on capital | -19.03% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -96.52M | -0.61% |
Cash from operations | -133.17M | -83.71% |
Cash from investing | -49.16M | -151.47% |
Cash from financing | 4.84M | 471.66% |
Net change in cash | -177.48M | -843.48% |
Free cash flow | -108.06M | -155.48% |
About
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Founded
2008
Website
Employees
487
